



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Lynkuet _ Veozah

Page: 1 of 2

Effective Date: 2/12/2026

Last Review Date: 1/26/2025

Applies to: New Jersey

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Lynkuet or Veozah under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Lynkuet

Lynkuet is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

Veozah

Veozah is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Applicable Drug List:

Lynkuet

Veozah

Policy/Guideline:

Coverage Criteria

The patient is unable to take the required number of formulary alternatives, two (2) for the given diagnosis, due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

Vasomotor Symptoms

Authorization may be granted when the requested drug is being prescribed for the treatment of moderate to severe vasomotor symptoms due to menopause.

Continuation of Therapy

Vasomotor Symptoms

Authorization may be granted when the requested drug is being prescribed for the treatment of moderate to severe vasomotor symptoms due to menopause when ALL of the following criteria are met:

- The patient has achieved or maintained a positive clinical response to the requested drug.
- The patient has been re-evaluated periodically to determine if treatment is still medically necessary.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Lynkuet _ Veozah

Page: 2 of 2

Effective Date: 2/12/2026

Last Review Date: 1/26/2025

Applies to: New Jersey

Approval Duration and Quantity Restrictions:

Initial and Renewal Approval: 12 months

Quantity Level Limit: Lynkuet - 60 capsules per 30 days / Veozah - 30 tablets per 30 days

References:

1. Lynkuet [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2025.
2. Veozah [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; December 2024.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 29, 2024.
4. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/29/2024).
5. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol.* 2014;123(1):202-216. doi:10.1097/01.AOG.0000441353.20693.78